Reduced paraoxonase 1 activities may explain the comorbidities between temporal lobe epilepsy and depression, anxiety and psychosis

Table 4 Measurement of paraoxonase enzymatic activity in healthy controls and subgroups of temporal lobe epilepsy patients

PON1 activities	HC	Pure TLE	F	df	P value	Partial eta squared
CMPAase (U/mL)	42.8 (1.7)	28.8 (1.9)	30.61	1/62	< 0.001	0.331
Arylesterase (U/mL)	215.4 (10.8)	156.4 (12.2)	13.47	1/62	0.001	0.178
		MTS
CMPAase (U/mL)	41.7 (1.5)	25.6 (1.2)	81.44	1/100	< 0.001	0.449
Arylesterase (U/mL)	209.8 (9.4)	139.4 (7.5)	36.98	1/100	< 0.001	0.270
		Pure MTS
CMPAase (U/mL)	42.2 (1.8)	27.3 (2.6)	22.61	1/52	< 0.001	0.303
Arylesterase (U/mL)	213.0 (10.8)	139.5	14.65	1/52	< 0.001	0.220

Data are results of univariate general linear model analysis and are shown as model-generated marginal estimated mean (SE) values after covarying for age, sex and body mass index. Pure TLE: Temporal lobe epilepsy without any psychiatric comorbidity; MTS: Established mesial temporal lobe sclerosis (thus including psychiatric comorbidities); Pure MTS: Established mesial temporal lobe sclerosis without any psychiatric comorbidity; TLE: Temporal lobe epilepsy; HC: Healthy controls; MTS: Mesial temporal sclerosis.